These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 9855321)

  • 1. Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration.
    Kovarik JM; Purba HS; Pongowski M; Gerbeau C; Humbert H; Mueller EA
    Pharmacotherapy; 1998; 18(6):1230-6. PubMed ID: 9855321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin.
    Kovarik JM; Rigaudy L; Guerret M; Gerbeau C; Rost KL
    Clin Pharmacol Ther; 1999 Oct; 66(4):391-400. PubMed ID: 10546923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics.
    Mueller EA; Kovarik JM; Uresin Y; Preisig-Flückiger SS; Hensel S; Lücker PW; Holt B
    J Clin Pharmacol; 1997 Nov; 37(11):1001-8. PubMed ID: 9505992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies.
    Smit JW; Oh C; Rengelshausen J; Terlinden R; Ravenstijn PG; Wang SS; Upmalis D; Mangold B
    Pharmacotherapy; 2010 Jan; 30(1):25-34. PubMed ID: 20030470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
    Bates SE; Bakke S; Kang M; Robey RW; Zhai S; Thambi P; Chen CC; Patil S; Smith T; Steinberg SM; Merino M; Goldspiel B; Meadows B; Stein WD; Choyke P; Balis F; Figg WD; Fojo T
    Clin Cancer Res; 2004 Jul; 10(14):4724-33. PubMed ID: 15269145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
    Cawello W; Rosenkranz B; Schmid B; Wierich W
    Epilepsia; 2013 Mar; 54(3):530-6. PubMed ID: 23360419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic study of infusional valspodar.
    Ma MK; McLeod HL; Westervelt P; Fracasso PM
    J Clin Pharmacol; 2002 Apr; 42(4):412-8. PubMed ID: 11936566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
    Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
    Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone.
    McCrea JB; Majumdar AK; Goldberg MR; Iwamoto M; Gargano C; Panebianco DL; Hesney M; Lines CR; Petty KJ; Deutsch PJ; Murphy MG; Gottesdiener KM; Goldwater DR; Blum RA
    Clin Pharmacol Ther; 2003 Jul; 74(1):17-24. PubMed ID: 12844131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
    Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
    Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
    Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects.
    Zannikos PN; Smit JW; Stahlberg HJ; Wenge B; Hillewaert VM; Etropolski MS
    J Opioid Manag; 2013; 9(4):291-300. PubMed ID: 24353023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, pharmacodynamics, and comparative bioavailability of single, oral 2-mg doses of dexamethasone liquid and tablet formulations: a randomized, controlled, crossover study in healthy adult volunteers.
    Queckenberg C; Wachall B; Erlinghagen V; Di Gion P; Tomalik-Scharte D; Tawab M; Gerbeth K; Fuhr U
    Clin Ther; 2011 Nov; 33(11):1831-41. PubMed ID: 22047811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part II: Quantifying its pharmacokinetic variability and refining the bioavailability estimate.
    Kovarik JM; Mueller EA; Richard F; Tetzloff W
    J Clin Pharmacol; 1997 Nov; 37(11):1009-14. PubMed ID: 9505993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients.
    Gelone DK; Park JM; Lake KD
    Pharmacotherapy; 2007 Sep; 27(9):1272-8. PubMed ID: 17723081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.